Abstract
Infections with HTLV-1 and -2 were detected in 12 (1.9%) and 6 (0.9%) indigenous individuals living in 27 Amazonian villages in Peru. All infections occurred in Shipibo-Konibo people. HTLV was more common among participants living in villages distant from larger port cities and women with non-monogamous sexual partners.
HTLV infection is concentrated in specific areas of Japan, Central and South Africa, the Caribbean, and Latin America. Among indigenous populations in Latin America, HTLV-1 infection has been reported in groups living in the Andean highlands, whereas HTLV-2 has been reported in groups living in the lowlands.1–3 Although several Latin American countries have reported the presence of HTLV among indigenous groups (Argentina, Bolivia, Brazil, Chile, Colombia, Panama, Paraguay, Peru, and Venezuela), it is difficult to estimate the HTLV prevalence among Amazonian indigenous groups, because there are few population-based studies.1–9
There are 71 different indigenous groups in Peru, and most HTLV-1 and -2 infections in indigenous groups have been reported in the Andean region among Quechua and Aymara populations, the two most populous indigenous groups in this area.8 In contrast, there is limited data about HTLV in the Amazon region. In the only published study of HTLV among Amazonian indigenous groups in Peru, two cases of HTLV-1 were detected; one case was in a Shipibo-Konibo village, and the other case was in a Kechwa-Lamas village. Additionally, two cases of HTLV-2 infection were detected; one case was in a Wampis village, and the other case was in a Harakmbut village.9
HTLV prevalence was higher in high-risk populations, such as female sex workers (FSWs) and men who have sex with men. The work by Wignall10 reported a 10.3% HTLV-1 prevalence among Peruvian FSWs who were born in the Amazon region.
HTLV is associated with adult T-cell leukemia/lymphoma and myelopathy/tropical spastic paraparesis (HAM/TSP)—diseases with a low incidence but high morbidity and mortality. HTLV-1 is also associated with increased rates of tuberculosis, uveitis, infective dermatitis, and strongyloidiasis.11 In this study, we sought to determine the prevalence and factors associated with HTLV infection in 27 indigenous communities living along the Peruvian Amazon basin.
Data presented herein were collected as part of a larger study of sexually transmitted infections (STIs) among Amazonian indigenous peoples conducted in 2007–2008 (Orellana ER, unpublished data). The study was an extension of the Peru PREVEN community-randomized trial.12 Study sites were remote indigenous villages, accessible mainly by boat, with some villages located up to a 12-hour boat ride from one of four major port cities in the Peruvian Amazon: Iquitos, Pucallpa, Yurimaguas, and Puerto Maldonado (Figure 1).
We recruited all eligible adults from villages with 30 or fewer eligible adults, and we took a random sample of 30 participants from each village with more than 30 eligible adults. Individuals were eligible if they were between 18 and 29 years old and had lived in the community for at least 6 months before recruitment. We excluded individuals who had resided outside the village for more than 3 of the 6 months before enrollment. Participants completed questionnaires that included an interviewer-administered component to collect demographic data and a self-administered component to capture more sensitive sexual behavior data based on a standardized population-based survey used in nationwide surveys of sexual behavior and STI/human immunodeficiency virus (HIV) of urban young adults.12 Participants also provided genital and blood samples for diagnosis of STI.
All HTLV testing was performed at the US Naval Medical Research Unit Six in Peru (NAMRU-6). HTLV-1 and -2 antibody testing was conducted using enzyme-linked immunosorbent assays (ELISAs; Vironostika, NC) with confirmatory Western blot assay (HTLV-1/2 Blot 2.4; Genelabs Diagnostics, Singapore). An individual was considered HTLV-1–seropositive if the ELISA was positive and confirmatory Western blot assay revealed bands representing gag (p24, p19), gp46, and two env proteins (GD21 and rgp 46-I). An individual was considered HTLV-2–seropositive if the ELISA was positive and confirmatory Western blot assay revealed bands representing p24, GD21, and rgp46-II. If gag and env proteins were absent but other HTLV-specific bands, such as p53 or p19, were present, the individual was considered indeterminate. Subjects with indeterminate results were excluded from the analysis.
Data were analyzed using STATA Version 8 (College Station, TX). Fisher exact and χ2 tests were used to assess the association between categorical variables. Unconditional logistic regression was used for bivariate analysis. This study was approved by the ethics committee at Universidad Peruana Cayetano Heredia and the NAMRU-6 in Peru.
A total of 644 eligible individuals agreed to participate. Of these participants, 638 agreed to provide a serum sample and were included in the analysis; 356 (55.8%) participants were females. The mean age of participants was 23 years (range = 18–29 years). The majority (53%) had a high school education or less, 95% were literate, and 60% were cohabitating. In general, indigenous villagers’ livelihoods depend on small-scale agriculture, fishing, other natural resource extraction, and commerce. The participants were from 27 villages that included 10 indigenous ethnic groups. The communities included were (1) Puerto Maldonado: three Ese eja, one Shipibo-Konibo, one Amarakaire (Harakmbut), and one Kichwaruna villages; (2) Yurimaguas: one Cocama-Cocamilla and five Shawi villages; (3) Iquitos: two Maijuna, one Murui, three Yagua, and one Bora villages; and (4) Pucallpa: eight Shipibo-Konibo villages.
The overall prevalence of HTLV-1 infection was 1.9% (12/638), and the overall prevalence of HTLV-2 infection was 0.9% (6/638). All infections were detected in eight of nine Shipibo-Konibo villages. The prevalence of HTLV-1 and -2 in this ethnic group was 4.1% (12/290) and 2.1% (6/290), respectively. HTLV-1 and -2 infections were significantly associated with the Shipibo-Konibo people (Table 1). All but one HTLV-2 infection occurred in villages where HTLV-1 infection was also detected; we did not detect anyone coinfected with both HTLV-1 and -2. Four test results were indeterminate. Two indeterminate results were detected in Shipibo-Konibo participants, and two indeterminate results were detected in Maijuna participants.
Table 1.
Variable | Number* (%) of HTLV negative† (N = 620) | Number* (%) of HTLV positive† (N = 18) | OR (CI) | P |
---|---|---|---|---|
Age in years (range) | ||||
18–20 | 186 (98.4) | 3 (1.6) | Reference | 0.39 |
21–25 | 263 (96.3) | 10 (3.7) | 2.36 (0.64–8.68) | |
26–30 | 171 (97.2) | 5 (2.8) | 1.81 (0.43–7.70) | |
Sex | ||||
Male | 275 (97.5) | 7 (2.5) | Reference | 0.65 |
Female | 345 (96.9) | 11 (3.1) | 1.25 (0.48–3.27) | |
Ethnic group | ||||
Shipibo-Konibo | 272 (93.8) | 18 (6.2) | ‡ | < 0.001 |
Other | 348 (100.0) | 0 | – | |
Educational level | ||||
High school or less | 327 (98.2) | 6 (1.8) | Reference | 0.09 |
Superior level | 280 (95.9) | 12 (4.1) | 2.34 (0.87–6.30) | |
Marital status | ||||
Single | 228 (98.3) | 4 (1.7) | Reference | 0.21 |
Married | 16 (100.0) | 0 | – | |
Cohabitating | 368 (96.6) | 13 (3.4) | 2.01 (0.65–6.25) | |
Separated | 7 (87.5) | 1 (12.5) | 8.14 (0.80–82.6) | |
Daily income | ||||
≥$1 US | 174 (99.4) | 1 (0.6) | Reference | 0.06 |
< $1 US | 432 (96.2) | 17 (3.8) | 6.85 (0.90–51.8) | |
Sexually active | ||||
Yes | 572 (97.4) | 15 (2.6) | 0.51 (0.11–2.32) | 0.38 |
No | 39 (95.1) | 2 (4.9) | Reference | |
Age in years at first intercourse | ||||
Never had sex | 38 (95.0) | 2 (5.0) | Reference | 0.26 |
< 11 | 23 (92.0) | 2 (8.0) | 1.65 (0.22–12.5) | |
11–15 | 294 (98.7) | 4 (1.3) | 0.26 (0.05–1.46) | |
16–20 | 201 (96.6) | 7 (3.4) | 0.66 (0.13–3.31) | |
21–25 | 7 (100.0) | 0 | – | |
26–30 | 0 | 1 (100.0) | – | |
Does not remember | 42 (97.7) | 1 (2.3) | 0.45 (0.04–5.19) | |
Lifetime number of sex partners | ||||
0–1 | 208 (96.7) | 7 (3.3) | Reference | 0.10 |
2–5 | 230 (99.1) | 2 (0.9) | 0.26 (0.05–1.26) | |
> 5 | 104 (97.2) | 3 (2.8) | 0.86 (0.22–3.38) | |
Does not remember | 65 (94.2) | 4 (5.8) | 1.83 (0.52–6.44) | |
Partner had another female partner | ||||
No | 209 (99.5) | 1 (0.5) | Reference | 0.02 |
Yes | 166 (97.1) | 5 (2.9) | 6.34 (0.73–54.8) | |
Do not know | 201 (95.7) | 9 (4.3) | 9.50 (1.19–75.7) |
Bonferroni correction (P < 0.0045).
Numbers may not add up to the total because of missing data.
Either HTLV-1 or -2.
OR cannot be calculated because of empty cells. P values were calculated using the Fisher exact test.
Of the nine Shipibo-Konibo villages included in the study, eight villages had participants who tested positive for HTLV-1 or -2. Of the eight villages, five villages were located less than 1 hour from the port city, and three villages were more than 1 hour from the port city. HTLV-1 and -2 prevalence in villages closer to the port city was 2% (4/205) and 0.5% (1/205), respectively. In villages farther from the port city, the prevalence was 9.4% (8/85) and 5.9% (5/85), respectively.
Presence of HTLV-1 or -2 infection was not significantly associated with age, sex, educational level, marital status, or income level. Prevalence of infection did not vary between participants who reported ever having sex and participants who did not. Also, prevalence did not vary by age of sexual debut or lifetime number of sex partners. Among participants who reported not ever having sex, two (4.9%) participants were positive for HTLV (one participant with HTLV-1 and one participant with HTLV-2), suggesting the presence of non-sexual transmission. Among females, not knowing whether her partner had other partners (odds ratio [OR] = 9.50, 95% confidence interval [CI] = 1.19–75.7) was positively associated with HTLV infection (Table 1). History of sexual abuse was present in 14.4% (49) of female participants. This abuse history was not associated with HTLV infection (OR = 2.02, 95% CI = 0.30–10.3). Among men, neither sex with a sex worker (OR = 2.0, 95% CI = 0.32–12.25) nor sex with another man (OR = 0.96, 95% CI = 0.11–8.45) was associated with HTLV infection.
This study is the second study to report HTLV infection in indigenous groups from the Peruvian Amazon. In our population-based study of 27 indigenous villages along the Peruvian Amazon basin, HTLV infection was detected exclusively in eight of nine Shipibo-Konibo villages. The overall prevalence rates of HTLV-1 (4.1%) and -2 (2.1%) in the Shipibo-Konibo ethnic group are similar to those rates reported previously among indigenous Peruvians.5–7 The prevalence of HTLV-1 and -2 was higher in individuals living in villages located farther from the port city than individuals living in villages closer to the port city. This finding suggests the long-term presence of HTLV in Amazonian indigenous populations rather than recent introduction into the community. There may be additional cultural practices of the Shipibo-Konibo ethnic group, such as shared breastfeeding, that maintain higher prevalence of HTLV infections over generations. We did not inquire specifically about such risk factors. HTLV infection was more common among women who did not know if their partners had other partners, suggesting that sexual transmission could be responsible for maintaining endemic infection. We did not find an association between HTLV infection and younger age of sexual debut or greater number of lifetime sex partners.
We included only villages located within a 12-hour radius from the port cities by boat and only participants between 18 and 29 years; therefore, we cannot extrapolate the results of this study to other indigenous Amazonian groups. Ethnographic research, phylogenetic analysis, molecular clock analysis, and mitochondrial DNA lineages studies of HTLV-1 and -2 infections could provide a better understanding of why HTLV infection is concentrated only in Shipibo-Konibo populations. Future studies should assess the presence of HTLV infection in neighboring indigenous groups (especially Wampis and Kechwa-Lamas) to determine if risk factors for infection differ by group.
ACKNOWLEDGMENTS
We would like to thank the indigenous health program and the regional organizations (ORAU, ORPIO, CORPI, and FENAMAD) of the Interethnic Association for the Development of the Peruvian Rainforest (AIDESEP) for their support in the development of this study. We also want to thank all of the indigenous leaders who helped us conduct this study and Monica Nieto for HTLV testing.
Disclaimer: The contents of this publication are the responsibility of the authors and do not necessarily reflect the views of the US Agency for International Development, the Department of the Navy, the Department of Defense, or the US Government. T.J.K. and S.M.M. are employees of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. § 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. § 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties.
Footnotes
Financial support: This work was supported by US Agency for International Development Sub-Award Agreement JOM-002 under Cooperative Agreement GPH-A-00-01-00007-00 between Pact Inc. and US Agency for International Development and National Institutes of Health Grant R01 NS055627 (to J.R.Z.).
Authors' addresses: Isaac E. Alva, Magaly M. Blas, Antonio Bernabe-Ortiz, Armando Cotrina, Marina Chiappe, Cesar P. Carcamo, and Patricia J. García, Epidemiology, STD/AIDS Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mails: alva@uw.edu, magaly.blas.b@upch.pe, antonio.bernabe@upch.pe, acotrina@gmail.com, marina.chiappe.g@upch.pe, cesar.carcamo@upch.pe, and patricia.garcia@upch.pe. E. Roberto Orellana, School of Social Work, Portland State University, Portland, OR, E-mail: orellana@pdx.edu. Tadeusz J. Kochel and Silvia M. Montano, US Naval Medical Research Unit No. 6 (NAMRU-6), Lima, Peru, E-mails: tad.kochel@med.navy.mil and Silvia.Montano@med.navy.mil. Joseph R. Zunt, Departments of Global Health, Epidemiology, Neurology and Medicine, University of Washington, Seattle, WA, E-mail: jzunt@u.washington.edu. Anne L. Buffardi, Department of Global Health, University of Washington, Seattle, WA, E-mail: buffardi@u.washington.edu.
References
- 1.Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266–281. doi: 10.1016/S1473-3099(07)70081-6. [DOI] [PubMed] [Google Scholar]
- 2.Carneiro-Proietti ABF, Catalan-Soares BC, Castro-Costa CM, Murphy EL, Sabino EC, Hisada M, Galvão-Castro B, Alcantara LC, Remondegui C, Verdonck K, Proietti FA. HTLV in the Americas: challenges and perspectives. Rev Panam Salud Publica. 2006;19:44–53. doi: 10.1590/s1020-49892006000100007. [DOI] [PubMed] [Google Scholar]
- 3.Shindo N, Alcantara LC, Van Dooren S, Salemi M, Costa MC, Kashima S, Covas DT, Teva A, Pellegrini M, Brito I, Vandamme AM, Galvão-Castro B. Human retroviruses (HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular epidemiology of HTLV type 2 isolates. AIDS Res Hum Retroviruses. 2002;18:71–77. doi: 10.1089/088922202753394736. [DOI] [PubMed] [Google Scholar]
- 4.Ishak R, Vallinoto AC, Azevedo VN, Ishak Mde O. Epidemiological aspects of retrovirus (HTLV) infection among Indian populations in the Amazon Region of Brazil. Cad Saude Publica. 2003;19:901–914. doi: 10.1590/s0102-311x2003000400013. [DOI] [PubMed] [Google Scholar]
- 5.Carneiro-Proietti AB, Catalan-Soares B, Proietti FA. Human T cell lymphotropic viruses (HTLV-I/II) in South America: should it be a public health concern? J Biomed Sci. 2002;9:587–595. doi: 10.1159/000067286. [DOI] [PubMed] [Google Scholar]
- 6.Zurita S, Costa C, Watts D, Indacochea S, Campos P, Sanchez J, Gotuzzo E. Prevalence of human retroviral infection in Quillabamba and Cuzco, Peru: a new endemic area for human T cell lymphotropic virus type 1. Am J Trop Med Hyg. 1997;56:561–565. doi: 10.4269/ajtmh.1997.56.561. [DOI] [PubMed] [Google Scholar]
- 7.Sanchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. Int J Infect Dis. 2003;7:132–137. doi: 10.1016/s1201-9712(03)90009-9. [DOI] [PubMed] [Google Scholar]
- 8.Fujiyoshi T, Li HC, Lou H, Yashiki S, Karino S, Zaninovic V, Oneegllo SG, Camacho M, Andrade R, Hurtado LV, Gomez LH, Damiani E, Cartier L, Dipierri JE, Hayami M, Sonoda S, Tajima K. Characteristic distribution of HTLV type I and HTLV type II carriers among native ethnic groups in South America. AIDS Res Hum Retroviruses. 1999;15:1235–1239. doi: 10.1089/088922299310124. [DOI] [PubMed] [Google Scholar]
- 9.Medeot S, Nates S, Recalde A, Gallego S, Maturano E, Giordano M, Serra H, Reategui J, Cabezas C. Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Am J Trop Med Hyg. 1999;60:623–629. doi: 10.4269/ajtmh.1999.60.623. [DOI] [PubMed] [Google Scholar]
- 10.Wignall FS, Hyams KC, Phillips IA, Escamilla J, Tejada A, Li O, Lopez F, Chauca G, Sanchez S, Roberts CR. Sexual transmission of human T-lymphotropic virus type I in Peruvian prostitutes. J Med Virol. 1992;38:44–48. doi: 10.1002/jmv.1890380110. [DOI] [PubMed] [Google Scholar]
- 11.Gonçalves DU, Proietti FA, Ribas JG, Araújo MG, Pinheiro SR, Guedes AC, Carneiro-Proietti AB. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23:577–589. doi: 10.1128/CMR.00063-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.García PJ, Holmes KK, Cárcamo CP, Garnett GP, Hughes JP, Campos PE, Whittington WL. Peru PREVEN Study Team Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised trial. Lancet. 2012;379:1120–1128. doi: 10.1016/S0140-6736(11)61846-1. [DOI] [PMC free article] [PubMed] [Google Scholar]